These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 29470615)

  • 1. Pre-dosing with lilotomab prior to therapy with
    Stokke C; Blakkisrud J; Løndalen A; Dahle J; Martinsen ACT; Holte H; Kolstad A
    Eur J Nucl Med Mol Imaging; 2018 Jul; 45(7):1233-1241. PubMed ID: 29470615
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Red Marrow-Absorbed Dose for Non-Hodgkin Lymphoma Patients Treated with 177Lu-Lilotomab Satetraxetan, a Novel Anti-CD37 Antibody-Radionuclide Conjugate.
    Blakkisrud J; Løndalen A; Dahle J; Turner S; Holte H; Kolstad A; Stokke C
    J Nucl Med; 2017 Jan; 58(1):55-61. PubMed ID: 27587710
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biodistribution and Dosimetry Results from a Phase 1 Trial of Therapy with the Antibody-Radionuclide Conjugate
    Blakkisrud J; Holtedahl JE; Løndalen A; Dahle J; Bach-Gansmo T; Holte H; Nygaard S; Kolstad A; Stokke C
    J Nucl Med; 2018 Apr; 59(4):704-710. PubMed ID: 28848035
    [No Abstract]   [Full Text] [Related]  

  • 4. Tumor-Absorbed Dose for Non-Hodgkin Lymphoma Patients Treated with the Anti-CD37 Antibody Radionuclide Conjugate 177Lu-Lilotomab Satetraxetan.
    Blakkisrud J; Løndalen A; Martinsen AC; Dahle J; Holtedahl JE; Bach-Gansmo T; Holte H; Kolstad A; Stokke C
    J Nucl Med; 2017 Jan; 58(1):48-54. PubMed ID: 27493270
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FDG PET/CT and Dosimetric Studies of
    Løndalen A; Blakkisrud J; Revheim ME; Dahle J; Kolstad A; Stokke C
    Mol Imaging Biol; 2022 Oct; 24(5):807-817. PubMed ID: 35486292
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FDG PET/CT parameters and correlations with tumor-absorbed doses in a phase 1 trial of
    Løndalen A; Blakkisrud J; Revheim ME; Madsbu UE; Dahle J; Kolstad A; Stokke C
    Eur J Nucl Med Mol Imaging; 2021 Jun; 48(6):1902-1914. PubMed ID: 33196921
    [TBL] [Abstract][Full Text] [Related]  

  • 7.
    Malenge MM; Patzke S; Ree AH; Stokke T; Ceuppens P; Middleton B; Dahle J; Repetto-Llamazares AHV
    J Nucl Med; 2020 Oct; 61(10):1468-1475. PubMed ID: 32245896
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Myelosuppression in patients treated with
    Blakkisrud J; Løndalen A; Dahle J; Martinsen AC; Kolstad A; Stokke C
    Acta Oncol; 2021 Nov; 60(11):1481-1488. PubMed ID: 34425735
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Radiation dosimetry results and safety correlations from 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin's lymphoma: combined data from 4 clinical trials.
    Wiseman GA; Kornmehl E; Leigh B; Erwin WD; Podoloff DA; Spies S; Sparks RB; Stabin MG; Witzig T; White CA
    J Nucl Med; 2003 Mar; 44(3):465-74. PubMed ID: 12621016
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase 1/2a study of 177Lu-lilotomab satetraxetan in relapsed/refractory indolent non-Hodgkin lymphoma.
    Kolstad A; Illidge T; Bolstad N; Spetalen S; Madsbu U; Stokke C; Blakkisrud J; Løndalen A; O'Rourke N; Beasley M; Jurczak W; Fagerli UM; Kaščák M; Bayne M; Obr A; Dahle J; Rojkjaer L; Pascal V; Holte H
    Blood Adv; 2020 Sep; 4(17):4091-4101. PubMed ID: 32877524
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Radioimmunotherapy of non-Hodgkin's lymphoma with 90Y-DOTA humanized anti-CD22 IgG (90Y-Epratuzumab): do tumor targeting and dosimetry predict therapeutic response?
    Sharkey RM; Brenner A; Burton J; Hajjar G; Toder SP; Alavi A; Matthies A; Tsai DE; Schuster SJ; Stadtmauer EA; Czuczman MS; Lamonica D; Kraeber-Bodere F; Mahe B; Chatal JF; Rogatko A; Mardirrosian G; Goldenberg DM
    J Nucl Med; 2003 Dec; 44(12):2000-18. PubMed ID: 14660727
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Myeloablative 131I-tositumomab radioimmunotherapy in treating non-Hodgkin's lymphoma: comparison of dosimetry based on whole-body retention and dose to critical organ receiving the highest dose.
    Rajendran JG; Gopal AK; Fisher DR; Durack LD; Gooley TA; Press OW
    J Nucl Med; 2008 May; 49(5):837-44. PubMed ID: 18413376
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dosimetric analysis of 177Lu-DOTA-rituximab in patients with relapsed/refractory non-Hodgkin's lymphoma.
    Yadav MP; Singla S; Thakral P; Ballal S; Bal C
    Nucl Med Commun; 2016 Jul; 37(7):735-42. PubMed ID: 26974315
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High-dose (131)I-tositumomab (anti-CD20) radioimmunotherapy for non-Hodgkin's lymphoma: adjusting radiation absorbed dose to actual organ volumes.
    Rajendran JG; Fisher DR; Gopal AK; Durack LD; Press OW; Eary JF
    J Nucl Med; 2004 Jun; 45(6):1059-64. PubMed ID: 15181141
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dosimetric analysis of 177Lu-cG250 radioimmunotherapy in renal cell carcinoma patients: correlation with myelotoxicity and pretherapeutic absorbed dose predictions based on 111In-cG250 imaging.
    Stillebroer AB; Zegers CM; Boerman OC; Oosterwijk E; Mulders PF; O'Donoghue JA; Visser EP; Oyen WJ
    J Nucl Med; 2012 Jan; 53(1):82-9. PubMed ID: 22159179
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dosimetric analysis of radioimmunotherapy with 186Re-labeled bivatuzumab in patients with head and neck cancer.
    Postema EJ; Börjesson PK; Buijs WC; Roos JC; Marres HA; Boerman OC; de Bree R; Lang M; Munzert G; van Dongen GA; Oyen WJ
    J Nucl Med; 2003 Oct; 44(10):1690-9. PubMed ID: 14530488
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination of
    Repetto-Llamazares AHV; Malenge MM; O'Shea A; Eiríksdóttir B; Stokke T; Larsen RH; Dahle J
    Eur J Haematol; 2018 Oct; 101(4):522-531. PubMed ID: 29993152
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I/II 90Y-Zevalin (yttrium-90 ibritumomab tiuxetan, IDEC-Y2B8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodgkin's lymphoma.
    Wiseman GA; White CA; Stabin M; Dunn WL; Erwin W; Dahlbom M; Raubitschek A; Karvelis K; Schultheiss T; Witzig TE; Belanger R; Spies S; Silverman DH; Berlfein JR; Ding E; Grillo-López AJ
    Eur J Nucl Med; 2000 Jul; 27(7):766-77. PubMed ID: 10952488
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of rituximab treatment on (90)Y-ibritumomab dosimetry for patients with non-Hodgkin lymphoma.
    Shen S; Forero A; Meredith RF; Shah JJ; Knox SJ; Wiseman GA; Usrey ME; Lobuglio AF
    J Nucl Med; 2010 Jan; 51(1):150-7. PubMed ID: 20008989
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor-Absorbed Dose Predicts Progression-Free Survival Following (131)I-Tositumomab Radioimmunotherapy.
    Dewaraja YK; Schipper MJ; Shen J; Smith LB; Murgic J; Savas H; Youssef E; Regan D; Wilderman SJ; Roberson PL; Kaminski MS; Avram AM
    J Nucl Med; 2014 Jul; 55(7):1047-53. PubMed ID: 24842891
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.